ANNOUNCING FDA 510(K) CLEARANCE FOR TEMPUS ECG-LOW EF /// READ MORE ANNOUNCING FDA 510(K) CLEARANCE FOR TEMPUS ECG-LOW EF /// READ MORE

Related Content

View more
  • post image
    07/01/2025

    Transforming R&D with Generative AI and Real-World Data

    Mike Yasiejko, General Manager and Executive Vice President at Tempus, recently spoke with Andrew Mazar, PhD, Chief Operating Officer at Actuate Therapeutics, about the ways Tempus’ liquid biopsy (xF+) and methylation assays have been valuable to Actuate’s work and how the company has benefitted from the partnership

    Watch now
  • post image
    06/12/2025

    AI & ML in action: Demonstrating real-world impact in trial design & patient care

    Discover how the Tempus platform leverages AI and ML to inform standard of care practices through health equity guidelines and drive insights that help refine clinical trial design. Engage with live demonstrations showcasing how our tools identify patients by modifying inclusion/exclusion criteria and leveraging patient queries. Explore how our tools integrate NCCN guidelines and empower life science teams to access current, actionable patient-journey insights. Learn how these real-world applications can drive progress in your clinical development initiatives.

    Secure your recording now.

    Watch replay
  • post image
    03/25/2025

    The RNA advantage: A multimodal approach to accelerating oncology R&D

    Discover how transcriptomic data and multi-omics data integrated with AI is helping revolutionize oncology drug development and patient care and fueling precision medicine 2.0. Learn about RNA sequencing’s role in companion diagnostics and Tempus Loop’s capabilities to support target identification and validation.

    Secure your recording now.

    Watch replay